Medvi vs Ivim Health: Program Mechanics and Medication Pathway

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Full head-to-head: PlexusDx vs MEDVi →

This is an independent editorial review. PlexusDx has no commercial relationship with Medvi or Ivim Health, and no affiliate links or paid placements are involved.

Medvi and Ivim Health are close cousins in the telehealth GLP-1 world: both pair virtual care with compounded dispensing. When two programs share a model, the meaningful comparison is in the mechanics — how each runs intake, prescribing, and fulfillment — and in what both quietly leave off the intake form. As of April 2026, each is one of dozens of options in this space.

The telehealth-plus-compounding model both share

Both Medvi and Ivim Health follow the same three-step spine: an online clinical evaluation, a provider-issued prescription, and dispensing of either brand-name FDA-approved GLP-1 therapy or compounded semaglutide and tirzepatide through licensed compounding pathways. Sharing a model means the differences live in execution rather than concept — the pace of clinician follow-up, how dose adjustments are handled, shipping reliability, and how transparent each program is about total cost. Those operational details, not the headline pitch, are what separate two services that look nearly identical on paper.

What distinguishes the Ivim program

Ivim Health (Ivim) runs its own telehealth-plus-compounded-pharmacy program, with medication options, care cadence, and pricing that change over time. The current specifics are posted at Ivim Health's official website, which is the reliable reference at the moment you read this.

What distinguishes the Medvi program

Medvi (Medvi Wellness) operates the same telehealth-plus-compounded-pharmacy structure, with its own intake flow and fulfillment terms detailed on Medvi's official website. Across the category, all-in monthly totals commonly land in the $200—$700+ range once evaluation, medication, and dispensing are combined — verify the current figure on each site before committing.

The research base under GLP-1 therapy

Whichever program dispenses them, the compounds carry the same evidence. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide act on appetite, satiety, and gastric emptying, with trial support from STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Mechanics differ between programs; the pharmacology does not, which is why execution and cost, not the compound, decide the comparison here.

Genes that shape the starting line

Neither intake asks about the genetics behind your metabolism. Variants in FTO, GLP1R (the receptor every GLP-1 compound binds), MC4R, and TCF7L2 map the appetite, satiety, and glucose-handling terrain a protocol operates on. They are pathway-level markers, not predictors of response to any one drug, but they add context. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including those genes.

The PlexusDx genetics-first path

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — with the genetic read added. When two programs share a model, that upstream context is the real differentiator.

Not affiliated: PlexusDx has no commercial ties to Medvi or Ivim Health and received no compensation for this review.

Related reading on PlexusDx: GLP 1 Hormone, What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist.

Disclaimer: This article is educational. PlexusDx is not affiliated with Medvi or Ivim Health and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

How are Medvi and Ivim Health structurally similar?

Both use a telehealth-plus-compounded-pharmacy model: an online evaluation, a provider-issued prescription, and dispensing of brand-name or compounded GLP-1 therapy. Because they share this spine, the practical differences appear in intake flow, care cadence, follow-up, and pricing rather than in the underlying concept or the medications themselves.

How do I compare two programs with the same model?

Focus on execution: what medications and doses are offered, how provider follow-up works, fulfillment speed, and total monthly cost. Since the model is shared, these operational details — posted on each brand's own site — are where Medvi and Ivim Health actually diverge.

Does the genetic test recommend a specific program?

No. It does not rank programs or predict response to any compound. The Precision Peptide Genetic Test maps pathway-level variants in FTO and MC4R, and TCF7L2 to describe your baseline biology, giving you context to discuss with a provider regardless of which program you choose.

What does PlexusDx add beyond the shared model?

PlexusDx runs the same compounded dispensing but layers an upstream genetic read on top. That pathway-level insight on FTO, MC4R is context neither Medvi nor Ivim Health builds into intake, and it is the clearest point of difference.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education